Biogen Inc has been the subject of numerous financial transactions by investment firms and individual investors. Notably,
Mirae Asset Global Investments,
Asset Management One Co. Ltd., and
Sumitomo Mitsui Trust Group Inc. have increased their shareholdings. In contrast,
Money Concepts Capital Corp,
New York State Teachers Retirement System, and
Kintegral Advisory LLC have reduced their stakes. In research and development news,
Phase III Felzartamab trials have begun for kidney diseases, with the new phase 3 trial targeting 36,000 patients with a rare kidney disease with no approved treatments.
BIIB080, Biogen's investigational
Tau-Targeting Therapy, has been awarded FDA Fast Track Designation for Alzheimer’s Disease treatment. Positive phase 1 results have been reported for
Salanersen in SMA treatment. Amid a domestic manufacturing boom, Biogen is considered one of the best pharma stocks to invest in. Various price target adjustments have also been announced, with RBC Capital notably increasing their target. Lastly, the company has announced a new global headquarters and innovation hub in Kendall Square and entered into a billion-dollar partnership with
City Therapeutics for CNS disease treatments.
Biogen BIIB News Analytics from Wed, 30 Oct 2024 07:00:00 GMT to Sat, 05 Jul 2025 05:57:29 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor 3
